Gilead Secures Three Solid Tumor T-Cell Engagers from Vir Biotech in $1.9B Deal

Key points

• Gilead is licensing three T-cell engagers from Vir Biotechnology’s PRO-XTEN platform for a total potential value of $1.9 billion.
• Vir receives $90 million upfront, comprising $65 million cash and a $25 million equity investment priced at a 30% premium.
• Gilead holds exclusive rights to nominate candidates and will handle subsequent development, manufacturing, and commercialization.
• The deal includes up to $45 million in near-term preclinical milestones and up to $1.74 billion in additional development, regulatory, and commercial milestones.
• Vir’s CEO Marianne De Backer stated the targets were not of interest to Vir, allowing the company to focus on its own programs.
• Gilead’s executive vice president of research, Flavius Martin, highlighted the combination of Gilead’s oncology capabilities with Vir’s discovery expertise.

Background

Vir Biotechnology has previously licensed its PRO-XTEN technology to Astellas in February 2026 for a potential $1.7 billion deal, focusing on a PSMAxCD3 candidate for prostate cancer. Gilead Sciences has been expanding its oncology portfolio through several acquisitions this year, including Arcellx for $7.8 billion and Tubulis for $3.15 billion upfront. Gilead’s CEO Dan O’Day has indicated that the company’s diversification into oncology and immunology has reached a critical mass, with future M&A activities focusing on complementing this foundation. Vir’s internal pipeline includes a HER2 T-cell engager, VIR-5818, with phase 1 data expected later this year, and the company is exploring indications for this molecule.

How outlets are covering it

Fierce Biotech emphasizes the strategic fit of the deal, highlighting Vir’s ability to focus on its own programs while generating non-dilutive funding, and Gilead’s focus on next-generation immunotherapies. Endpoints News confirms the financial terms, noting the $65 million upfront payment, but provides limited additional detail due to paywall restrictions. Both sources agree on the core terms and the significance of the PRO-XTEN platform, but Fierce Biotech provides more context on the broader M&A landscape and Vir’s internal pipeline.

Why it matters

This deal underscores the growing importance of T-cell engagers in solid tumor oncology, a challenging area due to toxicity concerns. Vir’s PRO-XTEN platform offers a potential solution by masking the T-cell engager until it reaches the tumor, reducing off-target effects. For Gilead, the deal complements its recent acquisitions and addresses clinical setbacks with its flagship solid tumor product, Trodelvy. For Vir, the deal provides significant non-dilutive funding and validates its technology platform, potentially paving the way for further partnerships. The deal also highlights the competitive landscape in oncology, with both companies actively seeking to expand their portfolios through strategic collaborations.

What to watch

Vir will handle the discovery, design, and optimization of the three T-cell engager candidates, while Gilead will assume responsibility for subsequent development, manufacturing, and commercialization. The two companies have already selected the targets for the three programs, though Vir declined to characterize the proposed indications further. Vir is expected to report registrational data for its hepatitis delta combo, elebsiran and tobevibart, soon, which could impact its competitive position against Gilead’s Hepcludex. Additionally, Vir plans to advance its PSMA T-cell engager, VIR-5500, into phase 3 next year in collaboration with Astellas. Gilead will continue to integrate the licensed candidates into its oncology pipeline, potentially addressing gaps in its solid tumor offerings.